Elvitegravir

Structural formula
General
Surname	Elvitegravir
other names	6- (3-chloro-2-fluorobenzyl) -1 - [(2 S ) -1-hydroxy-3-methyl-2-butanyl] -7-methoxy-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid ( IUPAC ) ;
Molecular formula	C 23 H 23 ClFNO 5
External identifiers / databases
PubChem	5277135
ChemSpider	4441060
DrugBank	DB09101
Wikidata	Q2740966
Drug information
ATC code	J05 OAX
properties
Molar mass	447.9 g mol −1
Physical state	firmly
safety instructions
	Please note the exemption from the labeling requirement for drugs, medical devices, cosmetics, food and animal feed
GHS labeling of hazardous substances	no GHS pictograms
	no GHS pictograms
H and P phrases	H: no H-phrases
	P: no P-phrases
	As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Elvitegravir is a chemical compound from the group of quinolones and integrase in the treatment of HIV infection. To achieve an effective concentration in the blood, elvitegravir is used together with cobicistat or ritonavir . The combination preparation is taken orally once a day.

Contraindications

Elvitegravir is broken down by CYP3A . Contraindications are substances that activate the gene expression of CYP3A, e.g. B. rifampicin , carbamazepine , phenobarbital , phenytoin and hypericin , as these lead to an increased breakdown of elvitegravir. Elvitegravir is also glucuronylated by UGT1A1 and UGT1A3 and then excreted via the kidneys . UGT1A1 and UGT1A3 can be inhibited by ritonavir or other HIV protease inhibitors , which reduces glucuronylation and increases the concentration of elvitegravir.

Trade names

Elvitegravir is sold in the United States under the brand name Vitekta . A combination preparation of elvitegravir with cobicistat, emtricitabine and tenofovir is marketed in the USA under the name Stribild and with tenofovir alafenamide instead of tenofovir as Genvoya .

literature

NR Unger, MV Worley, JJ Kisgen, EM Sherman, LM Childs-Kean: Elvitegravir for the treatment of HIV. In: Expert opinion on pharmacotherapy. Volume 17, number 17, December 2016, pp. 2359-2370, doi : 10.1080 / 14656566.2016.1250885 , PMID 27767362 .

Individual evidence

↑ ^a ^b Elvitegravir data sheet from Sigma-Aldrich , accessed on September 7, 2017 ( PDF ).

↑ T. Wills, V. Vega: Elvitegravir: a once-daily inhibitor of HIV-1 integrase. In: Expert opinion on investigational drugs. Volume 21, Number 3, March 2012, pp. 395-401, doi : 10.1517 / 13543784.2012.658914 , PMID 22321026 .

↑ D. Zhang, TJ Chando, DW Everett, CJ Patten, SS Dehal, WG Humphreys: In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. In: Drug metabolism and disposition: the biological fate of chemicals. Volume 33, Number 11, November 2005, pp. 1729-1739, doi : 10.1124 / dmd.105.005447 , PMID 16118329 .

^ PE Sax, E. DeJesus, A. Mills, A. Zolopa, C. Cohen, D. Wohl, JE Gallant, HC Liu, L. Zhong, K. Yale, K. White, BP Kearney, J. Szwarcberg, E . Quirk, AK Cheng: Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomized, double-blind, phase 3 trial, analysis of results after 48 weeks. In: Lancet. Volume 379, Number 9835, June 2012, pp. 2439-2448, doi : 10.1016 / S0140-6736 (12) 60917-9 , PMID 22748591 .

↑ SL Greig, ED Deeks: elvitegravir / cobicistat / emtricitabine / tenofovir Alafenamide: A Review in HIV-1 infection. In: Drugs. Volume 76, Number 9, June 2016, pp. 957-968, doi : 10.1007 / s40265-016-0586-z , PMID 27189707 .

[Sigma-1] Elvitegravir data sheet from Sigma-Aldrich , accessed on September 7, 2017 ( PDF ).

[2] T. Wills, V. Vega: Elvitegravir: a once-daily inhibitor of HIV-1 integrase. In: Expert opinion on investigational drugs. Volume 21, Number 3, March 2012, pp. 395-401, doi : 10.1517 / 13543784.2012.658914 , PMID 22321026 .

[3] D. Zhang, TJ Chando, DW Everett, CJ Patten, SS Dehal, WG Humphreys: In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. In: Drug metabolism and disposition: the biological fate of chemicals. Volume 33, Number 11, November 2005, pp. 1729-1739, doi : 10.1124 / dmd.105.005447 , PMID 16118329 .

[4] PE Sax, E. DeJesus, A. Mills, A. Zolopa, C. Cohen, D. Wohl, JE Gallant, HC Liu, L. Zhong, K. Yale, K. White, BP Kearney, J. Szwarcberg, E . Quirk, AK Cheng: Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomized, double-blind, phase 3 trial, analysis of results after 48 weeks. In: Lancet. Volume 379, Number 9835, June 2012, pp. 2439-2448, doi : 10.1016 / S0140-6736 (12) 60917-9 , PMID 22748591 .

[5] SL Greig, ED Deeks: elvitegravir / cobicistat / emtricitabine / tenofovir Alafenamide: A Review in HIV-1 infection. In: Drugs. Volume 76, Number 9, June 2016, pp. 957-968, doi : 10.1007 / s40265-016-0586-z , PMID 27189707 .